Evidence map›Paper›PMID 38331661›Full record

ReviewVaccine2024

Resurgent rotavirus diarrhoea outbreak five years after introduction of rotavirus vaccine in Botswana, 2018.

Goitom G Weldegebriel, Charles Okot, Nokuthla Majingo, Nesredin J Oumer, Margaret Mokomane, Ndibo J Monyatsi, Thabo M Phologolo, Lenah Visagie, Kentse Moakofh, Marina Seobakeng and 4 more

Open access · hybridAbstract readReview
In one paragraph

Review in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Observational
  3. Review
  4. 14 years of rotavirus A surveillance: unusual dominance of equine-like G3P[8] genotype with DS-1-like genotype constellation after the pandemic, Belgium, 2009 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Goitom G WeldegebrielWorld Health Organization, Intercountry Support Team, East and Southern Africa, Harare, Zimbabwe. Electronic address: weldegebrielg@who.int.
Charles OkotWorld Health Organization African Regional Office, Brazzaville, Congo.
Nokuthla MajingoMinistry of Health and Wellness, Botswana.
Nesredin J OumerMinistry of Health and Wellness, Botswana.
Margaret MokomaneUniversity of Botswana.
Ndibo J MonyatsiWorld Health Organization, Botswana.
Thabo M PhologoloUniversity of Botswana.
Lenah VisagieMinistry of Health and Wellness, Botswana.
Kentse MoakofhWorld Health Organization, Botswana.
Marina SeobakengMinistry of Health and Wellness, Botswana.
Balcha G MasreshaWorld Health Organization African Regional Office, Brazzaville, Congo.
Mapaseka SeheriDepartment of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Richard MihigoWorld Health Organization African Regional Office, Brazzaville, Congo.
Jason M MwendaWorld Health Organization African Regional Office, Brazzaville, Congo.
Ministry of Health · BWWorld Health Organization Regional Office for Africa · CGUniversity of Botswana · BWSefako Makgatho Health Sciences University · ZAWorld Health Organization - Zimbabwe · ZW

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionBotswana had a resurgent diarrhea outbreak in 2018, mainly affecting children under five years old. Botswana introduced rotavirus vaccine (RotarixTM) into the national immunization programme in July 2012. Official rotavirus vaccine coverage estimates averaged 77.2% over the five years following introduction. MATERIALS AND

methodsThe outbreak was investigated using multiple data sources, including stool laboratory testing, immunization data review, water assessment, and vaccine storage assessment. We reviewed official reports of the routine immunization data from 2013 to 2017 and compared district-level rotavirus vaccine coverage with district-level attack rates during the outbreak.

resultsDuring the outbreak, a total of 228 stool samples were tested at the national health laboratory and 152 (67%) of the specimens were positive for rotavirus. A portion of adequate samples (80) were selected for referral to the Regional Reference Lab. The laboratory testing of 80 samples at the Regional Reference Laboratory in South Africa showed that 91% of the stool samples were positive for rotavirus, and the dominant strain 47/80 (58.7%) was G3P[8]. The immunization data showed that rotavirus vaccine coverage varied widely among districts, and there was no correlation between districts with high attack rates and those with low immunization coverage. Water assessment showed that some water sources were contaminated with E Coli. There was no problem with vaccine storage.

conclusionThe outbreak was caused by rotavirus G3P[8], a strain that was not common in the country prior to the outbreak. Despite the significant pressure and anxiety that outbreaks cause, the number of diarrhea cases and deaths were less compared to pre-vaccine era due to the impact of vaccination. This highlights the need for continuous implementation of high impact child survival interventions.

Indexed as

RotavirusRotavirus InfectionsRotavirus VaccinesBotswanaChild, PreschoolDiarrheaDisease OutbreaksEscherichia coliFecesGenotypeHumansInfantWaterRotavirus VaccinesWaterBotswanaDiarrheaGenotypeIDSROutbreakRotavirus

Identifiers

PMID38331661
PMCPMC10953700
OpenAlexW4391602172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.